Danapha Pharmaceutical JSC (HSTC:DAN) YoY EBITDA Growth: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:DAN Danapha Pharmaceutical JSC HSTC:DAN
31 GF Score
Price ₫25,000.00
! 1 Warning Sign
View Full Analysis

What is Danapha Pharmaceutical JSC YoY EBITDA Growth?

Danapha Pharmaceutical JSC HSTC:DAN +9.65% 31 YoY EBITDA Growth is 0.00% as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Danapha Pharmaceutical JSC's YoY EBITDA Growth for the quarter that ended in . 20 was 0.00%.

Danapha Pharmaceutical JSC's EBITDA per Share for the six months ended in . 20 was ₫0.00.

Danapha Pharmaceutical JSC YoY EBITDA Growth Related Terms

Danapha Pharmaceutical JSC YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Danapha Pharmaceutical JSC's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC YoY EBITDA Growth Chart

Danapha Pharmaceutical JSC Annual Data
Trend
YoY EBITDA Growth

Danapha Pharmaceutical JSC Semi-Annual Data
YoY EBITDA Growth
HSTC:DAN
31GF Score
Danapha Pharmaceutical JSC HSTC:DAN
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Danapha Pharmaceutical JSC YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Danapha Pharmaceutical JSC's YoY EBITDA Growth for the fiscal year that ended in . 20 is calculated as:

YoY EBITDA Growth (A: . 20 )
=(EBITDA per Share (A: . 20 )-EBITDA per Share (A: . 20 ))/ | EBITDA per Share (A: . 20 ) |
=(-)/ | |
=N/A %

Danapha Pharmaceutical JSC's YoY EBITDA Growth for the quarter that ended in . 20 is calculated as:

YoY EBITDA Growth (Q: . 20 )
=(EBITDA per Share (Q: . 20 )-EBITDA per Share (Q: . 20 )) / | EBITDA per Share (Q: . 20 ) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Danapha Pharmaceutical JSC (HSTC:DAN) has a YoY EBITDA Growth of 0.00% as of . 20. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Danapha Pharmaceutical JSC and its competitors.
Is Danapha Pharmaceutical JSC's YoY EBITDA Growth too high?
Danapha Pharmaceutical JSC's current YoY EBITDA Growth is 0.00%. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's YoY EBITDA Growth compare to ZTS and UTHR?
Danapha Pharmaceutical JSC's YoY EBITDA Growth of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Danapha Pharmaceutical JSC and its competitors. Danapha Pharmaceutical JSC's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Danapha Pharmaceutical JSC's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current YoY EBITDA Growth is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Danapha Pharmaceutical JSC Business Description

Address 253 Dung Si Thanh Khe, Da Nang, VNM
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
31GF Score

Get the complete analysis for HSTC:DAN

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫25,000.00
Price